drugset
drugset / Trial / NCT03233308

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT03233308 ↗

Phase 2 Completed 20 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo

Timeline

Start
2017-10-20
Primary completion
2018-04-19
Completion
2018-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule 0.02 % —

Indications

open-angle glaucoma